In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Avidity Biosciences Inc (NASDAQ: RNA) closed at $44.99 up 1.15% from its previous closing price of $44.48. In other words, the price has increased by $1.15 from its previous closing price. On the day, 0.96 million shares were traded. RNA stock price reached its highest trading level at $45.5 during the session, while it also had its lowest trading level at $44.1.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 03, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
On March 14, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $60.
Evercore ISI Upgraded its In-line to Outperform on May 22, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 06 ’24 when Boyce Sarah sold 28,000 shares for $43.35 per share. The transaction valued at 1,213,822 led to the insider holds 205,043 shares of the business.
LEVIN ARTHUR A sold 5,000 shares of RNA for $225,069 on Jul 19 ’24. The Director now owns 14,830 shares after completing the transaction at $45.01 per share. On Jul 09 ’24, another insider, Boyce Sarah, who serves as the President and CEO of the company, sold 28,000 shares for $39.93 each. As a result, the insider received 1,118,082 and left with 205,043 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 4939947008 and an Enterprise Value of 3649300736. For the stock, the TTM Price-to-Sale (P/S) ratio is 466.03 while its Price-to-Book (P/B) ratio in mrq is 4.03. Its current Enterprise Value per Revenue stands at 344.306 whereas that against EBITDA is -12.91.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $48.80, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 12.58%, while the 200-Day Moving Average is calculated to be 104.91%.
Shares Statistics:
For the past three months, RNA has traded an average of 1.59M shares per day and 1224010 over the past ten days. A total of 109.80M shares are outstanding, with a floating share count of 99.27M. Insiders hold about 9.59% of the company’s shares, while institutions hold 80.25% stake in the company. Shares short for RNA as of 1722384000 were 12952998 with a Short Ratio of 8.13, compared to 1719532800 on 10834579. Therefore, it implies a Short% of Shares Outstanding of 12952998 and a Short% of Float of 14.850000999999999.
